Welcome to our dedicated page for Centene Del news (Ticker: CNC), a resource for investors and traders seeking the latest updates and insights on Centene Del stock.
Centene Corporation (NYSE: CNC), a leading provider of government-sponsored healthcare programs, offers investors and stakeholders timely access to its latest developments through this centralized news hub. Track official press releases, regulatory filings, and strategic initiatives from the Fortune 500 company driving innovation in Medicaid managed care and Medicare Advantage plans.
This resource delivers essential updates including quarterly earnings reports, contract awards with state/federal agencies, partnerships advancing telehealth services, and expansions of behavioral health programs. Users will find verified information on Centene’s specialty services like pharmacy benefits management and corrections healthcare solutions.
Bookmark this page for direct access to CNC’s:
• Annual and quarterly financial performance
• Government program enrollment updates
• Strategic acquisitions in healthcare services
• Regulatory compliance milestones
Monitor Centene’s progress in addressing healthcare disparities through its integrated care models and value-based initiatives. Return regularly for unfiltered updates directly from corporate communications and SEC filings.
Centene Corporation (NYSE: CNC) announced that CEO Michael Neidorff will retire in 2022 but will continue as Executive Chairman until year-end. The Board initiated a succession plan earlier this year, now positioned to appoint a new CEO through an extensive search. Neidorff highlighted Centene's robust standing and leadership team, affirming confidence in a smooth transition. Under his leadership since 1996, Centene grew from a $40 million company to a $125 billion market leader, impacting 26.5 million members across the U.S. and internationally.
Centene Corporation (NYSE: CNC) hosted a virtual investor day on December 10, 2021, announcing its 2022 financial guidance and outlining a Value Creation Plan aimed at enhancing earnings growth and shareholder value. The company expects total revenues of $135.9 billion to $137.9 billion and diluted EPS of $4.07 to $4.23 for FY 2022. Key elements of the Value Creation Plan include SG&A savings, gross margin improvement, and strategic capital allocation, with an EPS target of $7.50 to $7.75 by 2024. The 2021 total revenue guidance reaffirms a range of $125.2 billion to $126.4 billion.
Centene Corporation (NYSE: CNC) announced that its 2022 Financial Guidance and Investor Day event, scheduled for December 10, 2021, will now be held virtually due to concerns over the COVID-19 Omicron variant. Initially planned as a hybrid event, it will now forgo in-person attendance. The event will be streamed live on Centene's investor relations website, providing updates on the company's financial outlook and strategies.
Centene is a major healthcare provider, emphasizing integrated services for underserved populations.
Health Net has appointed Colin Havert as the new Commercial Officer for Health Net of California. Havert, who previously spent over a decade at Anthem Blue Cross, will oversee the large group, small business group, and individual and family plan segments. This leadership change aims to ensure excellence and disciplined growth as Health Net seeks to enhance health equity and community health outcomes. The company serves approximately 3 million members with a wide array of health plans and services.
Centene Corporation (NYSE: CNC) announced its Arizona subsidiaries, Arizona Complete Health-Complete Care Plan and Care1st Health Plan Arizona, have been awarded a Competitive Contract Expansion by the Arizona Health Care Cost Containment System (AHCCCS). This three-year contract, starting Oct. 1, 2022, aims to enhance access to healthcare services for individuals with Serious Mental Illness. The contracts will cover around 22,000 beneficiaries in Northern and Southern Arizona, emphasizing a holistic approach to care addressing mental and physical health needs.
Centene Corporation (NYSE: CNC) will present at the Wolfe Research Virtual Healthcare Conference on November 17-18, 2021. The company is scheduled to participate on November 17 at 11:00 a.m. ET, with a live audio webcast available at this link. A replay will be accessible later through the company's investor relations page. Centene is a leading multi-national healthcare enterprise focused on improving health outcomes for under-insured and uninsured individuals.
Centene Corporation (NYSE: CNC) will participate in the Credit Suisse 30th Annual Healthcare Conference from November 8-11, 2021, presenting in virtual format on November 10 at 10:30 a.m. ET. A live audio webcast can be accessed here. A replay will be available on Centene's website under the Investors section. As a Fortune 25 company, Centene is dedicated to providing high-quality healthcare services to under-insured and uninsured individuals across various programs.
Centene Corporation (NYSE: CNC) announced its commitment to enhancing shareholder value and invited constructive ideas from Politan Capital Management. The company is pursuing a strategy aimed at creating value, targeting a 3.3% adjusted net income margin by 2024. In its latest quarterly earnings, Centene achieved an 11% revenue growth, while optimizing its cost structure. Noteworthy is the sale of a majority stake in U.S. Medical Management, with proceeds directed towards a stock repurchase program. Furthermore, Centene is actively refreshing its Board, adding four new independent directors over two years.
Health Net, a leading health plan in California, has announced the availability of Ambetter from Health Net health plans for individuals and families through CoveredCalifornia.com. These plans aim to provide affordable healthcare options, especially for those who do not qualify for
Centene Corporation (NYSE: CNC) announced the sale of a majority stake in U.S. Medical Management, LLC (USMM) to Rubicon Founders and other partners, retaining a minority interest. This strategic move aims to enhance USMM's reach in home-based healthcare, an area where it has demonstrated cost savings of $154 million for Medicare beneficiaries. Proceeds from the sale will be used for a stock repurchase program, indicating Centene's focus on shareholder value. The transaction is pending regulatory approval and customary closing conditions.